Abstract
Introduction
It is important yet difficult to maintain currency in clinical oncology practice. The emergence of new diagnostic technologies and new paradigms for cancer treatment combine to produce a rapidly changing clinical approach to patients aided by the increasing use of multidisciplinary care teams and development of evidence-based protocols.
Methods
Teams of experts review the literature in a given area and produce management guidelines and protocols for use by practicing clinicians. Traditionally within Hematology/Oncology, these guidelines have been directed to management of a given tumor type. However, in recent years, attention has increasingly turned to supportive oncology; for example, there are now management guidelines for conditions such as neutropenic fever [Hughes et al. Clinical Infectious Diseases 34(6):730–751, 2002], antiemetic (The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer Annals of Oncology 17:20–28, 2006) and most recently, mucositis [Rubenstein et al. Cancer 100(9 Suppl):2026–2046, 2004]. It is critical that any guideline process should include education, evaluation, and timely update in its remit, because guidelines become highly compromised if their existence is not widely known, if they do not facilitate clinical practice, or if they are not reflective of contemporary medical literature.
Results
The Mucositis Study Group (MSG) of the Multinational Association for Supportive Care in Cancer/International Society for Oral Oncology was created in 1998 to specifically address the multiprofessional approach to clinical care, research, and education associated with mucosal injury in cancer patients. A specific outcome has been the development of evidence-based guidelines for the management of mucositis [Rubenstein et al. Cancer 100(9 Suppl):2026–2046, 2004; The Mucositis Study Group of MASCC/ISSO 2005]. The original guidelines [Rubenstein et al. Cancer 100(9 Suppl):2026–2046, 2004] and a companion paper discussing the science behind mucositis [Sonis et al. Cancer 100(9):1995–2025, 2004], were published in 2004. The MSG has recently updated the guidelines [The Mucositis Study Group of MASCC/ISSO 2005].
Discussion
This paper discusses the process involved and the lessons learned that might help other groups planning to undertake a similar project.
Similar content being viewed by others
References
Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751
The Anti-emetic Subcommittee of the Multinational Association of Supportive Care in Cancer (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia international antiemetic consensus conference. Ann Oncol 17:20–28
Rubenstein EB, Peterson DE, Schubert M et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046
The Mucositis Study Group of MASCC/ISOO (2005) Summary of evidence-based clinical practice guidelines for care of patients with oral and gastrointestinal mucositis (2005 update). http://www.mascc.org
Sonis ST, Elting LS, Keefe, D et al (2004) Perspectives on cancer therapy-induced mucosal injury. Cancer 100(9):1995–2025 (Suppl)
Somerfield MR, Padberg JJ, Pfister DG et al (2000) ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Class Pap Curr Comments 4:881–886
Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49:749–754
Keefe DM (2004) Gastrointestinal mucositis: a new biological model. Support Care Cancer 12:6–9
Sonis ST, Peterson DE, McGuire DB, Williams DA (eds) (2001) Mucosal injury in cancer patients: new strategies for research and treatment. J Natl Cancer Inst 29:1–54
Elting LS, Sonis ST, Keefe DM (2004) Educational session. Proc Am Soc Clin Oncol
McGuire, DB, Johnson, J, Migliorati, C (2006) Promulgation of guidelines for mucositis management: educating health care professionals and patients (MSG paper 9). Support Care Cancer (in press)
Spielberger R, Stiff P, Bensinger W et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590–2598
Stiff PJ, Emmanouilides C, Bensinger WI, et al (2006) Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem cell transplantation setting. J Clin Oncol 24:1–8
Peterson D, Keefe D, Hutchins R and Schubert M (2005) Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice. Support Care Cancer (in press)
Jones J, Avritsher E, Cooksley C, Michelet M, Nebiyou Bekele B, Elting L (2005) Epidemiology of treatment associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer (in press)
Anthony L, Bowen J, Garden A, Hewson I, Sonis S (2005) New thoughts on the pathobiology of regimen-related mucosal injury. Support Care Cancer (in press)
von Bultzingslowen I, Brennan M, Spijkervet F, Logan R, Stringer A, Raber J, Keefe DM (2005) Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer (in press)
Altman A, Barasch A, Damato K, Elad S, Epstein J (2005) Antimicrobials, mucosal coating agents, anesthetics, analgesics and nutritional supplements in alimentary mucositis. Support Care Cancer (in press)
Migliorati C, Oberle-Edwards L, Schubert M (2005) The role of alternative and natural agents, ice, and laser in the management of alimentary tract mucositis. Support Care Cancer (in press)
McGuire D, Johnson J, Wienandts P, Correa E (2005) The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer (in press)
Lalla R, Schubert M, Bensadoun R-J, Keefe D (2005) Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer (in press)
Bensadoun R-J, Schubert M, Lalla R, Keefe D (2005) Amifostine in the management of radiation-induced and chemotherapy-induced alimentary mucositis. Support Care Cancer (in press)
Keefe D, Lees J, Horvath N (2005) Palifermin for oral mucositis: the royal adelaide hospital experience. Support Care Cancer (in press)
Brennan M, von Bultzingslowen I, Schubert M, Keefe D (2005) Alimentary mucositis: putting the guidelines into practice. Support Care Cancer (in press)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Keefe, D.M., Peterson, D.E. & Schubert, M.M. Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls. Support Care Cancer 14, 492–498 (2006). https://doi.org/10.1007/s00520-006-0059-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-006-0059-0